ABCAM PLC Result of AGM (9914L)

TIDMABC

RNS Number : 9914L

ABCAM PLC

18 May 2022

For immediate release

18 May 2022

ABCAM PLC

("Abcam" or the "Company")

Result of Annual General Meeting

Abcam plc (AIM: ABC; NASDAQ: ABCM), a global leader in the supply of life science research tools, announces that all resolutions put to its Annual General Meeting (the "AGM") held today were passed.

The Board is pleased that all resolutions have been approved by shareholders and notes that a minority of shareholders opposed Resolution 2 (advisory resolution to approve the Annual Report on Remuneration) and Resolution 3 (to approve the Remuneration Policy).

For the reasons stated in the Annual Report, t he Board and the Remuneration Committee continue to believe that the Remuneration Policy aligns incentives to the long-term success of the business and the creation of sustainable long-term shareholder value.

The Board remains firmly committed to speaking with shareholders to ensure it fully understands their views and it will continue to constructively engage with those shareholders who were unable to support Resolutions 2 and 3.

Full details of the poll results are available at corporate.abcam.com .

For further information, please contact:

 
                                              + 44 (0) 1223 696 
Abcam                                          000 
Marc Perkins, Company Secretary 
Numis - Nominated Advisor & Joint Corporate 
 Broker                                       + 44 (0) 20 7260 1000 
Freddie Barnfield / Duncan Monteith 
Morgan Stanley - Joint Corporate Broker       + 44 (0) 207 425 8000 
Tom Perry / Luka Kezic 
FTI Consulting                                + 44 (0) 20 3727 1000 
Ben Atwell / Julia Bradshaw

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

Please visit corporate.abcam.com to find out more.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, as well as statements that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: a regional or global health pandemic, including the novel coronavirus and its related variants ("COVID-19"), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavours; failing to successfully use, access and maintain information systems and implement new systems to handle our changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current and potential future growth; any significant interruptions in our operations; if our products fail to satisfy applicable quality criteria, specifications and performance standards; failing to maintain our brand and reputation; our dependence upon management and highly skilled employees and our ability to attract and retain these highly skilled employees; and the important factors discussed under the caption "Risk Factors" in Abcam's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission ("SEC") on 22 October 2020, which is on file with the SEC and is available on the SEC website at www.sec.gov, as such factors may be updated from time to time in Abcam's other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBKFBBQBKDQPD

(END) Dow Jones Newswires

May 18, 2022 11:30 ET (15:30 GMT)

Abcam (LSE:ABC)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024